Roche is the recipient of the new approval, getting the go-ahead from the US regulator for its PATHWAY HER2 (4B5) test to ...

Seagen hailed the outcome of the lawsuit, saying it will now seek royalties on all future US sales of Enhertu through the remaining lifespan of the patent, which expires in November 2024.

According to GlobalData’s Pharma Intelligence Center, the drug is projected to reach $13.9bn in sales by 2030. GlobalData is the parent company of Pharmaceutical Technology. Despite Enhertu’s ...

Daiichi Sankyo recognizes Enhertu sales in the U.S. AstraZeneca reports its share of gross profit margin from Enhertu sales in the U.S. as Alliance Revenue in the company’s financial statements.

Sales of Enhertu in the US are recognised by Daiichi Sankyo. AstraZeneca reports its share of gross profit margin from Enhertu sales in the US as Alliance Revenue in the Company's financial ...

Sales of Enhertu in the US are recognised by Daiichi Sankyo. AstraZeneca reports its share of gross profit margin from Enhertu sales in the US as Alliance Revenue in the Company’s financial statements ...

Daiichi Sankyo recognizes the U.S. sales of Enhertu while AstraZeneca records its share of gross profit margin from Enhertu sales under Alliance revenues. In the first nine months of 2024 ...

(AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive ...